1. The Future is Now: Advancing Blood-Based Markers

   • Maria C. Carrillo
   • R. M. Edelmayer
   • H. M. Snyder

   Editorial 16 October 2022 Pages: 563 - 564

2. Blood-Based Biomarkers for Alzheimer’s Disease: Are We There Yet?

   • Pierre Tariot

   Editorial 16 October 2022 Pages: 565 - 566

3. What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer’s Disease Can Be Used in Clinical Practice?

   • Tobias Bittner

   Editorial 16 October 2022 Pages: 567 - 568

4. Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force

   • Davide Angioni
   • J. Delrieu
   • EU/US/CTAD Task Force

   CTAD Task Force Paper Open access 12 October 2022 Pages: 569 - 579

5. The role of Aβ in Alzheimer’s Disease as an Evolutionary Outcome of Optimized Innate Immune Defense

   • Marc Tatar

   Review Open access 31 August 2022 Pages: 580 - 588

   

6. A Hierarchical Bayesian Latent Class Model for the Diagnostic Performance of Mini-Mental State Examination and Montreal Cognitive Assessment in Screening Mild Cognitive Impairment Due to Alzheimer’s Disease

   • Xiaonan Wang
   • Fengjie Li
   • Qi Gao

   Review 29 August 2022 Pages: 589 - 600

   

7. Effectiveness of Physical Exercise on Alzheimer’s disease. A Systematic Review

   • R. Cámara-Calmaestra
   • A. Martínez-Amat
   • A. Achalandabaso-Ochoa

   Review 07 June 2022 Pages: 601 - 616

   

8. Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid

   • Roy Yaari
   • K. C. Holdridge
   • A4 Study Team

   Original Research Open access 07 June 2022 Pages: 617 - 624

   

9. Adjudicating Mild Cognitive Impairment Due to Alzheimer’s Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial

   • Lon S. Schneider
   • D. A. Bennett
   • C. Chiang

   Original Research Open access 02 September 2022 Pages: 625 - 634

   

10. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults

    • M. H. Silverman
    • S. Duggan
    • B. Wallner

    Original Research 29 August 2022 Pages: 635 - 645

    

11. Intervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer’s Symptomatic Expression (INCREASE) Study: Results from a Randomized Controlled Study of Medication Therapy Management Targeting a Delay in Prodromal Dementia Symptom Progression

    • Daniela C. Moga
    • E. L. Abner
    • G. A. Jicha

    Original Research 31 May 2022 Pages: 646 - 654

    

12. Association of a MIND Diet with Brain Structure and Dementia in a French Population

    • Aline Thomas
    • S. Lefèvre-Arbogast
    • C. Samieri

    Original Research 09 August 2022 Pages: 655 - 664

    

13. Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites

    • Elizabeth K. Rhodus
    • P. Aisen
    • R. Raman

    Original Research 21 September 2022 Pages: 665 - 671

    

14. Recruitment of Older African Americans in Alzheimer’s Disease Clinical Trials Using a Community Education Approach

    • A. R. Shaw
    • J. Perales-Puchalt
    • Eric D. Vidoni

    Original Research 27 September 2022 Pages: 672 - 678

    

15. Delayed Decline of Cognitive Function by Antihypertensive Agents: A Cohort Study Linked with Genotype Data

    • Zohara Sternberg
    • R. Podolsky
    • B. Schaller

    Original Research 06 September 2022 Pages: 679 - 691

    

16. Sex Moderates the Association between Frailty and Mild Behavioral Impairment

    • D. X. Guan
    • K. Rockwood
    • Zahinoor Ismail

    Original Research Open access 21 June 2022 Pages: 692 - 700

    

17. Obesity and Brain Health: The Impact of Metabolic Syndrome and Cardiorespiratory Fitness on Cognitive Performances in Middle-Aged Obese Women

    • W. Wichayanrat
    • S. Boripuntakul
    • Somporn Sungkarat

    Original Research 26 May 2022 Pages: 701 - 707

18. Age, Sex, Hypertension and HDL-C Alter Serum BACE1 Activity in Cognitively Normal Subjects: Implications for Alzheimer’s Disease

    • C. Cervellati
    • A. Vergallo
    • G. Zuliani

    Original Research 21 September 2022 Pages: 708 - 714

    

19. Antihypertensive Agents and Incident Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Observational Studies

    • M. Adesuyan
    • Y. H. Jani
    • Ruth Brauer

    Original Research Open access 28 September 2022 Pages: 715 - 724

    

20. Association of Preeclampsia with Incident Dementia and Alzheimer’s Disease among Women in the Framingham Offspring Study

    • Kanran Wang
    • Kaining Guo
    • Qin Zhou

    Original Research 21 June 2022 Pages: 725 - 730

    

21. Sex-Driven Differences in the Effectiveness of Individualized Clinical Management of Alzheimer’s Disease Risk

    • N. Saif
    • H. Hristov
    • Richard S. Isaacson

    Original Research Open access 26 April 2022 Pages: 731 - 742

22. Objective and Subjective Measurements of Motor Function: Results from the HELIAD Study

    • F. Kalligerou
    • G. Paraskevas
    • Nikolaos Scarmeas

    Original Research 29 August 2022 Pages: 743 - 751

    

23. Salivary Alpha-Amylase Activity and Mild Cognitive Impairment among Japanese Older Adults: The Toon Health Study

    • N. Yamane
    • A. Ikeda
    • Takeshi Tanigawa

    Original Research 14 May 2022 Pages: 752 - 757

    

24. Evaluation of the Fiscal Costs and Consequences of Alzheimer’s Disease in Germany: Microsimulation of Patients’ and Caregivers’ Pathways

    • R. Martins
    • N. Kotsopoulos
    • Mark P. Connolly

    Original Research Open access 26 May 2022 Pages: 758 - 768

    

25. In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum

    • Mario Torso
    • G. R. Ridgway
    • Alzheimer’s Disease Neuroimaging Initiative

    Original Research Open access 16 June 2022 Pages: 769 - 779

    

26. Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

    • Claude M. Wischik
    • P. Bentham
    • B. O. Schelter

    Original Research Open access 26 June 2022 Pages: 780 - 790

    

27. Cognitive Digital Biomarkers from Automated Transcription of Spoken Language

    • N. Tavabi
    • D. Stück
    • Rhoda Au

    Original Research Open access 13 July 2022 Pages: 791 - 800

    

28. Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults

    • M. A. Dubbelman
    • J. Sanchez
    • A4 Study team, full listing of team and site personnel available at A4STUDΥ.org

    Original Research 16 June 2022 Pages: 801 - 808

    

29. Validation of the Saint Louis University Quality of Life Questionnaire in Older Adults with Alzheimer’s Disease

    • K. Y. Yamashita
    • E. S. Deol
    • T. K. Malmstrom

    Brief Report 16 June 2022 Pages: 809 - 812

    

30. Beyond Frailty in Alzheimer’s Disease: Should We Move to the Concept of Intrinsic Capacity?

    • Antoine Garnier-Crussard
    • V. Dauphinot
    • P. Krolak-Salmon

    Letter to the Editor Open access 14 September 2022 Pages: 813 - 815

    

31. Genetically Determined Alzheimer’s Disease Is Associated with Increased Risk of Varicose Vein: A Mendelian Randomization Study

    • C. Zheng
    • Ruijie Zeng

    Letter to the Editor 16 September 2022 Pages: 816 - 817